On June 26, Arcutis Biotherapeutics Inc. announced that ZORYVE (roflumilast) cream 0.15% received a strong recommendation in ...

Intermittent treatment with pimecrolimus over 1 year significantly reverses corticosteroid-induced skin atrophy and ...

A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on ...

Organon’s VTAMA ® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis. The American Academy of ...

Once-daily roflumilast cream at 0.15% improved symptoms of atopic dermatitis (AD) across multiple end points. According to investigators of the phase 3 studies that uncovered the findings ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates that initiating ruxolitinib cream therapy for atopic ...

Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.

Efficacy and Tolerability of Roflumilast Cream 0.15% for Atopic Dermatitis: Pooled Subgroup Analysis of Patients with Face/Eyelid Involvement from Phase 3 INTEGUMENT-1/2 TrialsSimpson, E et al.

Nektar Therapeutics (NASDAQ: NKTR) stock exploded nearly 157% following news that Rezpeg, the company’s experimental ...

Efficacy and Tolerability of Roflumilast Cream 0.15% for Atopic Dermatitis: Pooled Subgroup Analysis of Patients with Face/Eyelid Involvement from Phase 3 INTEGUMENT-1/2 Trials Simpson, E et al.

The“INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis” Open Label Extension (INTEGUMENT-OLE) was a Phase 3, multicenter, open-label extension study of ...